A combined biomarker and clinical panel for chronic graft versus host disease diagnosis.
A combined biomarker and clinical panel for chronic graft versus host disease diagnosis.
复制标题
用于慢性移植物与宿主疾病诊断的合并生物标志物和临床面板。
DOI：
10.1002/cjp2.58
复制
发表时间：
2017-01
期刊：
影响因子：
--
通讯作者：
Sarwal MM
中科院分区：
文献类型：
--
作者：
Pidala J;Sigdel TK;Wang A;Hsieh S;Inamoto Y;Martin PJ;Flowers ME;Hansen JA;Lee SJ;Sarwal MM
虽然之前已经报道了许多慢性移植物抗宿主病（cGVHD）生物标志物，但很少有在独立的cGVHD队列中得到验证。我们的目的是在多中心慢性GVHD联盟中验证先前报道的cGVHD标志物的诊断准确性。在59例cGVHD病例和33例匹配的非GVHD对照中，共评估了42种RNA和18种蛋白质候选生物标志物。从PBMC中分离总RNA，并使用PCR定量RNA标志物。使用ELISA定量血清蛋白标志物。组合的3种RNA生物标志物（IRS 2、PLEKHF 1和IL 1 R2）和2种临床变量（受体CMV血清状态和预处理方案强度）组准确地（AUC 0.81）将cGVHD病例与对照分开。其他研究的RNA和蛋白质标记物并未被证实为准确的cGVHD诊断生物标记物。所研究的标志物未能分离较高风险的cGVHD（根据总体NIH 0 - 3评分，以及与经典cGVHD状态的重叠）。这些数据支持需要进行多项独立的验证研究，以用于cGVHD诊断生物标志物的最终临床应用。
Whilst many chronic graft versus host disease (cGVHD) biomarkers have been previously reported, few have been verified in an independent cGVHD cohort. We aimed to verify the diagnostic accuracy of previously reported markers of cGVHD in a multi‐centre Chronic GVHD Consortium. A total of 42 RNA and 18 protein candidate biomarkers were assessed amongst 59 cGVHD cases and 33 matched non‐GVHD controls. Total RNA was isolated from PBMC, and RNA markers were quantified using PCR. Serum protein markers were quantified using ELISA. A combined 3 RNA biomarker (IRS2, PLEKHF1 and IL1R2) and 2 clinical variables (recipient CMV serostatus and conditioning regimen intensity) panel accurately (AUC 0.81) segregated cGVHD cases from controls. Other studied RNA and protein markers were not confirmed as accurate cGVHD diagnostic biomarkers. The studied markers failed to segregate higher risk cGVHD (per overall NIH 0‐3 score, and overlap versus classic cGVHD status). These data support the need for multiple independent verification studies for the ultimate clinical application of cGVHD diagnostic biomarkers.